Some new, and not so new, anti-inflammatory targets

Current Opinion in Pharmacology

Volumn 5, Issue 4 SPEC. ISS., 2005, Pages 394-397

  Simmons, David L ^a   Buckley, Christopher D ^b  

^a PFIZER INC   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADALIMUMAB; ALEFACEPT; B7 ANTIGEN; CD28 ANTIGEN; CELL ADHESION MOLECULE; CYCLOOXYGENASE 2 INHIBITOR; EFALIZUMAB; ETANERCEPT; G PROTEIN COUPLED RECEPTOR; INFLIXIMAB; LECTIN; NATALIZUMAB; STEROID; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR;

ADOPTIVE IMMUNOTHERAPY; AUTOIMMUNITY; BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG APPROVAL; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; EDITORIAL; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; INFECTION; INFLAMMATION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 21644467902     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.05.001     Document Type: Editorial

References (0)